Everest Medicines Limited announced that the Taiwan Food and Drug Administration (TFDA) has approved the New Drug Application (NDA) for XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). XERAVA® was approved by the National Medical Products Administration ("NMPA") of China in March 2023 and commercially launched in July. It has also been approved and commercialized in Singapore.

XERAVA® has been recommended by multiple treatment guidelines in China and globally, based on its broad bacterial spectrum coverage and high potency against multidrug-resistant bacterial infections.